PMID- 36389692
OWN - NLM
STAT- MEDLINE
DCOM- 20221121
LR  - 20221122
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 13
DP  - 2022
TI  - Haploidentical donor stem cell transplantation had a lower incidence of 
      bronchiolitis obliterans syndrome compared with HLA-matched sibling donor 
      transplantation in patients with hematologic malignancies: Benefit from ATG?
PG  - 1036403
LID - 10.3389/fimmu.2022.1036403 [doi]
LID - 1036403
AB  - BACKGROUND: Haploidentical donor stem cell transplantation (HID-SCT) based on 
      antithymocyte globulin (ATG) for graft-versus-host disease (GVHD) prophylaxis had 
      achieved a similar incidence of chronic graft-versus-host disease (cGVHD) with 
      human leukocyte antigen (HLA)-matched sibling donor stem cell transplantation 
      (MSD-SCT). However, bronchiolitis obliterans syndrome (BOS), which serves as 
      pulmonary cGVHD, was rarely compared between HID and MSD transplantation. 
      METHODS: One thousand four hundred five patients with hematologic malignancies 
      who underwent allogeneic SCT were enrolled in this retrospective study. Based on 
      donor type, we divided the patients into three groups: HID, MSD, and match 
      unrelated donor (MUD) groups. The cumulative incidences and risk factors of BOS 
      were analyzed. RESULTS: The 5-year cumulative incidence of BOS was 7.2% in the 
      whole population. HID transplantation had a lower 5-year cumulative incidence of 
      BOS than MSD transplantation (4.1% vs. 10.0%, p < 0.001) and a similar incidence 
      with MUD transplantation (4.1% vs. 6.2%, p = 0.224). The 5-year cumulative 
      incidence of BOS was lower in the ATG group than that in the non-ATG group in 
      both the whole and MSD populations (4.6% vs. 11.2%, p < 0.001, and 4.1% vs. 
      11.2%, p = 0.042, respectively). The 5-year incidence of BOS in mixed grafts 
      [peripheral blood stem cell (PBSC) plus bone marrow] group was also lower than 
      that in the PBSC group (4.2% vs. 9.1, p = 0.001). Multivariate analysis showed 
      that HID, ATG, and mixed grafts were protective factors for BOS [odds ratio (OR) 
      0.3, 95% CI 0.2-0.6, p < 0.001; OR 0.3, 95% CI 0.2-0.7, p = 0.001; OR 0.3, 95% CI 
      0.1-0.8, p = 0.013], and acute graft-versus-host disease (aGVHD) and cGVHD were 
      independent risk factors for BOS (OR 2.1, 95% 1.1-4.3, p = 0.035; OR 10.1, 95% CI 
      4.0-25.0, p < 0.001). CONCLUSIONS: HID transplantation had a lower incidence of 
      BOS than MSD transplantation, which might be associated with ATG and mixed 
      grafts.
CI  - Copyright (c) 2022 Weng, Fan, Xue, Huang, Xu, Jin, Yu, Ye, Fan, Xuan and Liu.
FAU - Weng, Guangyang
AU  - Weng G
AD  - Department of Hematology, Nanfang Hospital, Southern Medical University, 
      Guangzhou, China.
AD  - Department of Hematology, First Affiliated Hospital of Shenzhen University, The 
      Second People's Hospital of Shenzhen, Shenzhen, China.
FAU - Fan, Zhiping
AU  - Fan Z
AD  - Department of Hematology, Nanfang Hospital, Southern Medical University, 
      Guangzhou, China.
FAU - Xue, Huiwen
AU  - Xue H
AD  - Department of Hematology, Nanfang Hospital, Southern Medical University, 
      Guangzhou, China.
FAU - Huang, Fen
AU  - Huang F
AD  - Department of Hematology, Nanfang Hospital, Southern Medical University, 
      Guangzhou, China.
FAU - Xu, Na
AU  - Xu N
AD  - Department of Hematology, Nanfang Hospital, Southern Medical University, 
      Guangzhou, China.
FAU - Jin, Hua
AU  - Jin H
AD  - Department of Hematology, Nanfang Hospital, Southern Medical University, 
      Guangzhou, China.
FAU - Yu, Sijian
AU  - Yu S
AD  - Department of Hematology, Nanfang Hospital, Southern Medical University, 
      Guangzhou, China.
FAU - Ye, Zhixin
AU  - Ye Z
AD  - Department of Hematology, Nanfang Hospital, Southern Medical University, 
      Guangzhou, China.
FAU - Fan, Jingchao
AU  - Fan J
AD  - Department of Hematology, First Affiliated Hospital of Shenzhen University, The 
      Second People's Hospital of Shenzhen, Shenzhen, China.
FAU - Xuan, Li
AU  - Xuan L
AD  - Department of Hematology, Nanfang Hospital, Southern Medical University, 
      Guangzhou, China.
FAU - Liu, Qifa
AU  - Liu Q
AD  - Department of Hematology, Nanfang Hospital, Southern Medical University, 
      Guangzhou, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20221027
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - 0 (Antilymphocyte Serum)
RN  - 0 (HLA Antigens)
RN  - 0 (Histocompatibility Antigens Class II)
SB  - IM
MH  - Humans
MH  - Antilymphocyte Serum/therapeutic use
MH  - *Graft vs Host Disease/epidemiology/etiology/prevention & control
MH  - Incidence
MH  - Siblings
MH  - Transplantation Conditioning
MH  - Retrospective Studies
MH  - *Hematopoietic Stem Cell Transplantation/adverse effects
MH  - *Hematologic Neoplasms/therapy/etiology
MH  - HLA Antigens
MH  - *Bronchiolitis Obliterans/epidemiology/etiology
MH  - Unrelated Donors
MH  - Histocompatibility Antigens Class II
PMC - PMC9646562
OTO - NOTNLM
OT  - GVHD
OT  - antithymocyte globulin
OT  - bronchiolitis obliterans syndrome
OT  - graft
OT  - haploidentical donor stem cell transplantation
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/11/18 06:00
MHDA- 2022/11/22 06:00
PMCR- 2022/01/01
CRDT- 2022/11/17 12:43
PHST- 2022/09/04 00:00 [received]
PHST- 2022/10/07 00:00 [accepted]
PHST- 2022/11/17 12:43 [entrez]
PHST- 2022/11/18 06:00 [pubmed]
PHST- 2022/11/22 06:00 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2022.1036403 [doi]
PST - epublish
SO  - Front Immunol. 2022 Oct 27;13:1036403. doi: 10.3389/fimmu.2022.1036403. 
      eCollection 2022.